Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone

Fertility and sterility, 76(5), 1057-1059

DOI 10.1016/s0015-0282(01)02843-6 PMID 11704136 Source

Abstract

Objective

To determine the metabolic and reproductive effectiveness of rosiglitazone in polycystic ovary syndrome (PCOS).

Design

Case report.

Setting

Academic clinical practice and General Clinical Research Center. PATIENT(S): A 25-year-old woman with PCOS. INTERVENTION(S): Rosiglitazone maleate, 4 mg daily for 5 months until conception. MAIN OUTCOME MEASURE(S): Insulin sensitivity by steady-state plasma glucose technique; serum androgens, progesterone, and hCG; and pelvic ultrasound images. RESULT(S): Rosiglitazone treatment for 5 months improved insulin sensitivity, lowered serum free testosterone, and resulted in spontaneous ovulation and conception. CONCLUSION(S): Rosiglitazone is a promising insulin sensitizer for treatment of PCOS. Clinical trials are warranted.

Topics

rosiglitazone pcos ovulation induction, insulin sensitizers polycystic ovary syndrome, thiazolidinedione fertility treatment pcos, insulin resistance pcos pregnancy, metabolic treatment pcos spontaneous ovulation, rosiglitazone hyperandrogenism treatment, insulin sensitivity pcos conception, root cause pcos treatment ovulation, thiazolidinediones anovulation therapy, pcos insulin sensitizer case report

Cite this article

Cataldo, N. A., Abbasi, F., McLaughlin, T. L., Lamendola, C., & Reaven, G. M. (2001). Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone. *Fertility and sterility*, *76*(5), 1057-1059. https://doi.org/10.1016/s0015-0282(01)02843-6

Related articles